Premium
Chemoprevention of exprimental bladder cancer
Author(s) -
Moon Richard C.,
Detrisac Carol J.,
Thomas Cathy F.,
Kelloff Gary J.
Publication year - 1992
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.240501326
Subject(s) - bladder cancer , cancer research , cancer , medicine , oncology
The chemopreventive efficacy of several compounds was evaluated in the N ‐ butyl ‐ N ‐(4‐hydroxybuty) introsamine (OH)‐BBN)‐induced urinary bladder cancer model using C57BL/6xDBA/2F 1 (BDF) male mice. Compounds were administered in a defined semipurified diet (AIN‐76‐A) either as single agents orin combination. As single agents and at the doses emplyed, 2‐α‐difluoromethylornithine (DFMO), piroxicam, oltpraz, and sodium moybdate effectively inhibited the incidence of trasitional cell carcinoma (TCC). 4‐Hydroxyphenyl retinamide (4‐HPR) was ineffective. Body weight gain and survival was not affected by thedoses of agents used. Combinations of two agents which increased efficacy were 4‐HPR+DFMO, DFMO+piroxicam, 4‐HPR+oltipraz, and DFMO+oltiprz. Three‐agent combinations which showed enhanced efficacy against TCC induction were 4‐HPR+Namolybdate+DFMO, 4‐HPR+DFMO+piroxicam, and 4‐HPR+DFMO+oltipraz. Although the three‐agent combinations were, for the most part, no more effective than the two‐agent combinations at the doses employed, all combination regmens signicantly reduced bladder incidence even when single agent administration did not. © 1992 Wiley‐Liss, Inc.